{
    "id": 27474,
    "fullName": "SSTR1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SSTR1 positive indicates the presence of the SSTR1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6751,
        "geneSymbol": "SSTR1",
        "terms": [
            "SSTR1",
            "SRIF-2",
            "SS-1-R",
            "SS1-R",
            "SS1R"
        ]
    },
    "variant": "positive",
    "createDate": "02/22/2018",
    "updateDate": "02/22/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12909,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (NETTER-1) that supported FDA approval, Lutathera (lutetium Lu 177 dotatate) treatment combined with supportive care significantly improved progression-free survival rate at month 20 (65.2% vs 10.8%) and response rate (18% vs 3%) compared to supportive care alone in patients with somatostatin receptor-positive midgut neuroendocrine tumors (PMID: 28076709; NCT01578239).",
            "molecularProfile": {
                "id": 28965,
                "profileName": "SSTR1 positive"
            },
            "therapy": {
                "id": 6696,
                "therapyName": "lutetium Lu 177 dotatate",
                "synonyms": null
            },
            "indication": {
                "id": 50626,
                "name": "gastrointestinal neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10865,
                    "pubMedId": 28076709,
                    "title": "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28076709"
                },
                {
                    "id": 15573,
                    "pubMedId": null,
                    "title": "Lutathera (lutetium Lu 177 dotatate) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208700"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28965,
            "profileName": "SSTR1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}